Chrysantis Zeaxanthin Approved by FDA as NDI

Chrysantis Zeaxanthin Approved by FDA as NDI

WEST CHICAGO, Ill.ChrysantisInc. (www.chrysantis.com) announced it received notice from the Food and DrugAdministration (FDA) that the agency accepted the companys New DietaryIngredient (NDI) submission, allowing its EZ Eyes natural zeaxanthin to belegally sold in dietary supplements in the United States. The Chrysantis NDIapplication included toxicology and other company-sponsored studiesdemonstrating the safety of its compound, as well as epidemiological evidenceshowing the ingredient is safe for consumption at the recommended dosage by thegeneral U.S. population.

Extensive assistance on the research support and filingsubmission was provided by principals of Laguna Niguel, Calif.-basedIMAGINutrition. To bring a new ingredient to market within the guidelinesof DSHEA [the Dietary Supplement Health & Education Act of 1994] requiresspecific information be researched, gathered and submitted in the right format,said Anthony Almada, founder of IMAGINutrition. Fewer than30 percent of NDI applications submitted receive a favorable response, oftenbecause the information is not complete.